Caris Life Sciences to present CapeAI study predicting capecitabine response in ER+ breast cancer at ESMO 2026
Caris Life Sciences flagged eight AI-driven precision-oncology studies slated for presentation at the ESMO Congress 2026 in Madrid. Results have not yet been presented; posters are scheduled for Oct. 23—27, 2026, with Caris-led sessions on Oct. 25. Two Caris-led studies aim to improve breast-cancer treatment selection by predicting capecitabine response, risk, and endocrine-therapy benefit stratification. Collaborative posters extend the approach to lung cancer, endometrial cancer, melanoma, and immuno-oncology to support biomarker discovery and therapy-response prediction. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Caris Life Sciences Inc. published the original content used to generate this news brief via (Ref. ID: 202610140830PR_NEWS_USPR_____DA71516) on October 14, 2026, and is solely responsible for the information contained therein. (C)
Caris Life Sciences flagged eight AI-driven precision-oncology studies slated for presentation at the ESMO Congress 2026 in Madrid. Results have not yet been presented; posters are scheduled for Oct. 23—27, 2026, with Caris-led sessions on Oct. 25.
Two Caris-led studies aim to improve breast-cancer treatment selection by predicting capecitabine response, risk, and endocrine-therapy benefit stratification. Collaborative posters extend the approach to lung cancer, endometrial cancer, melanoma, and immuno-oncology to support biomarker discovery and therapy-response prediction. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice.
Caris Life Sciences Inc. published the original content used to generate this news brief via (Ref. ID: 202610140830PR_NEWS_USPR_____DA71516) on October 14, 2026, and is solely responsible for the information contained therein. (C)